SHAREHOLDERS ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Inotiv, Inc. - NOTV - Stock News Source

– Alakin will be used in a Parkinson’s study to start in Paris, France –

TORONTO, IN / ACCESS CABLE / August 2, 2022 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing artificial intelligence/machine learning technologies that address pressing societal needs, is pleased to announce that its minority-owned subsidiary, Tech2Heal SAS, has reported a second pilot study for its Alakin HEALTHwatch out BREASTmanagement Pplatform (“health.map” for short). Alakin is scheduled to launch in August 2022, with pilot studies beginning in hospitals and clinics in multiple locations, over a six-month trial period.

Alakin consists of a clinical dashboard for use by multidisciplinary care teams that interacts with a conversational mobile application for patient use (IOS and Android). Alakin is an easy-to-use, easily configurable “Swiss Army Knife” tool that promotes higher productivity of healthcare organizations while giving them the ability to create easily scalable engagement tools that link multidisciplinary care teams with their patients, both for monitoring and vertical digital therapy purposes. Alakin is available in five languages: English, French, Spanish, German and Portuguese.

In the second of a series of planned studies involving Alakin, a clinical research team in Paris, France is preparing to launch a digital therapy program for patients with Parkinson’s, a disease that affects 200,000 people in France. Alakin’s “no code” design allows this clinical team to effortlessly create and customize a complete vertical therapy process to support patients in their daily lives with a structured and adaptable program of follow-up and engagement. The research team will integrate digital biomarkers using the Alakin mobile app’s accelerometer, camera and microphone to aid in the diagnosis, monitoring and progression of disease progression in patients.

“We at AI/ML are excited about the potential and versatility of Alakin,” said Tim Daniels, president of AI/ML Innovations Inc. “In addition to Tech2Heal’s plans for the platform in Europe and South America, we also look forward to rolling out the technology into the North American market through AI/ML’s subsidiary, AI Rx Inc., which holds the North American distribution rights to this exciting technology. Parkinson’s currently affects nearly one million Americans, with 60,000 new cases diagnosed each year. This clinical study will demonstrate the malleability and applicability of Alakin in a variety of cases, such as its use as an aid for Parkinson’s.”

Alakin is a comprehensive model based on SaaS, HEALTHwatch out BREASTmanagement PLatform (“health.map”), designed for use by healthcare and pharmaceutical providers, was natively developed on FHIR standards to ensure high interoperability and is fully HIPAA compliant. Alakin consists of a clinical dashboard for multidisciplinary care teams and a conversational mobile application for patient use (IOS and Android). Alakin is available in five languages: English, French, Spanish, German and Portuguese. Alakin’s solution facilitates the delivery of connected care across any clinical condition, patient profile, and treatment plan, significantly increasing patient engagement and helping to reduce adverse events.

Alakin’s flexibility allows it to easily fit into any healthcare environment or workflow, from oncology to primary care, diabetes to hospital-to-home transition, or even mail-Acute care. This flexibility is made possible by a powerful care pathway builder. It enables clinicians to tailor care workflows to their needs and protocols, whether creating remote care programs from scratch or leveraging existing protocols from ICHOM standards. These workflows instantly transform into a conversational patient app, allowing patients to manage parts of their care process themselves.

Alakin has highly configurable features and a built-in suite of unique tools such as schedule management, collaboration tools, built-in telemedicine and chat, a triage dashboard, patient records, a prescription builder, a care pathway study and a mobile application for patients

About Tech2Heal

Tech2Heal is a healthcare innovator based in Paris, France, specializing in digital health technologies with the goal of creating a compassionate, collaborative, and patient-centric healthcare ecosystem. T2H has developed a portfolio of health technology products and services designed to improve a person’s mental and physical well-being through the use of a unique combination of proprietary digital assets and live remote advice.

Tech2Heal’s main products include:

Qookka – clinically supported and evidence-based digital therapy for anxious and depressed patients delivered through a secure digital platform

Alakin – one measure, digital HEALTHwatch out BREASTmanagement Pplatform (“health.map”) designed for healthcare and pharmaceutical providers. Assisted self-care becomes a reality for both patients and members of the care team.

For more information: https://www.tech2heal.com/

About AI/ML Innovations Inc.

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with a focus on early investment in digital health and wellness startups leveraging AI, ML and cloud computing. and digital platforms to power transformative healthcare management solutions and precision support delivery across the healthcare pipeline. Through strategic partnerships with Health Gauge (70% owned by AIML), Tech2Heal (up to 22% ownership rights, with 9.44% current ownership), AI Rx Inc. (70% owned by AIML) and other planned cumulative investments, the company continues to capitalize on the expansion of growth areas, to the benefit of all of the Company’s stakeholders. AI/ML shares are traded on the Canadian Stock Exchange under the symbol “AIML”, the OTCQB Venture Market under “AIMLF” and the Frankfurt Values Exchange under “42FB”.

On behalf of the Board of Directors
Tim Daniels, CEO

To learn more about AI/ML innovations:

For detailed information, please refer to the AI/ML website at https://aiml-innovations.com/ or the documents presented by the Company in sedar.com.
For more information: Blake Fallis at (778) 405-0882 or [email protected].
Corporate video: https://www.youtube.com/watch?v=k2QSjo7clXc&feature=youtu.be
Official YouTube channel: https://www.youtube.com/channel/UCCfOj2P_Fu3TOK6Jl1G9vEQ

Neither the CSE nor its Regulation Services Provider (as that term is defined in the CSE’s policies) accepts responsibility for the adequacy or accuracy of this release.

Cautionary and forward-looking statements

Certain information in this press release may contain forward-looking statements that involve material known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the Company’s control, including, but not limited to, the uncertainty of competition from other industry players, the impact of general economic conditions, of the industry, reliance on regulatory approvals, and the ability to raise additional capital as needed in the future. Readers are cautioned that the assumptions used in the preparation of such information, while believed to be reasonable at the time of preparation, may prove inaccurate and undue reliance should not be placed on forward-looking statements. Forward-looking statements in this Press release are expressly qualified by this warning statement.

The forward-looking statements in this Press release are made as of the date of this press release, and the Company undertakes no obligation to publicly update or revise any of the forward-looking statements contained therein, whether due to new information, future events or otherwise, except as expressly required by the applicable values. law.

FONT: AI/ML Innovations Inc.

See source version at access cable.com:
https://www.accesswire.com/710176/AIML-Innovations-Tech2Heal-Announces-Second-Pilot-Study-of-its-Proprietary-Healthcare-Management-Platform-Alakin

Source link

Leave a Reply

Your email address will not be published.